Emergent, Providence sign COVID-19 vaccine deal


Emergent BioSolutions signed a five-year deal with Providence Therapeutics worth an estimated $90 million to provide contract development and manufacturing organization services for its experimental COVID-19 vaccine candidate PTX-COVID19-B. The vaccine is being evaluated in midstage trials, and production is slated to begin next year.

Full story:

AIChE SmartBrief

Chemical engineering news

Designed specifically for chemical engineers, AIChE SmartBrief is a FREE weekly e-mail newsletter. It helps chemical engineers stay informed on the business and technology developments affecting our profession.